The Effect of Hepatic Steatosis on 18F-FDG Uptake in PET-CT Examinations of Cancer Egyptian Patients

Overview

Journal Eur J Hybrid Imaging

Date 2023 Oct 15

PMID 37840056

Authors

Magdi A Ali

Eman El-Abd

Mohamed Morsi

Mohamed M El Safwany

Mohamed Z El-Sayed

Affiliations

Soon will be listed here.

Abstract

Background: Hepatic steatosis is the most common chronic hepatic disease. Imaging diagnosis of hepatic steatosis has been evaluated as an alternative to invasive histological diagnosis.

Study Aims: The study aimed to assess the effect of hepatic steatosis on Flourine-18 fluorodeoxyglucose (18F-FDG) uptakes in cancer patients.

Patients And Methods: Blood samples were collected from 50 cancer patients and analyzed to calculate fatty liver index and Hepatic steatosis index (HIS). Hepatic steatosis examined using high-resolution ultrasound and positron emission tomography-computed tomography (PET-CT). Linear attenuation coefficient, standardized-uptake value (SUV) mean (SUV mean), and SUV maximum (SUVmax) were measured. Accordingly, patients were divided equally into non-fatty liver, and fatty liver groups.

Results: A significant increase in SUVmax and SUV mean was observed in the fatty liver group more than in the non-fatty liver group. HSI significantly increased in the fatty liver group compared to the non-fatty liver group. Liver tissue uptake FDG was significantly correlated with HSI values. SUV max significantly correlated with body mass index (BMI) in the non-fatty group only.

Conclusion: Hepatic changes in cancer patients affect the liver metabolic activity and thus the 18 F-FDG uptake. Therefore, further corrections should be considered when the liver is used as a comparator for PET-CT scans of cancer patients.

Citing Articles

Predictive role of [F]FDG PET-CT radiomic parameters for KRAS/BRAF/EGFR mutations in metastatic colorectal cancer patients.

Ali M, Zahra O, Morsi M, El Safwany M, El Feky S EJNMMI Rep. 2024; 8(1):42.

PMID: 39722096 PMC: 11669641. DOI: 10.1186/s41824-024-00233-5.

Molecular imaging of macrophage composition and dynamics in MASLD.

Yang B, Chan M, Heo G, Lou L, Luehmann H, Park C JHEP Rep. 2024; 6(12):101220.

PMID: 39624233 PMC: 11609525. DOI: 10.1016/j.jhepr.2024.101220.

Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.

Ionita-Radu F, Patoni C, Nancoff A, Marin F, Gaman L, Bucurica A Int J Mol Sci. 2024; 25(8).

PMID: 38673787 PMC: 11050387. DOI: 10.3390/ijms25084201.

Non-invasive PET imaging of liver fibrogenesis using a RESCA-conjugated Affibody molecule.

Wegrzyniak O, Lechi F, Mitran B, Cheung P, Bitzios A, Persson J iScience. 2024; 27(5):109688.

PMID: 38660405 PMC: 11039342. DOI: 10.1016/j.isci.2024.109688.

References

Keramida G, Roldao Pereira L, Kaya G, Peters A . Hepatic and splenic F-FDG blood clearance rates (Ki) in hepatic steatosis and diabetes mellitus. Clin Physiol Funct Imaging. 2019; 40(2):99-105. DOI: 10.1111/cpf.12610. View

Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S . Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015; 19(5):597-601. PMC: 4566337. DOI: 10.4103/2230-8210.163172. View

Oh R, Hustead T, Ali S, Pantsari M . Mildly Elevated Liver Transaminase Levels: Causes and Evaluation. Am Fam Physician. 2018; 96(11):709-715. View

Zhang X, Gao X, Zhang P, Guo Y, Lin H, Diao X . Dynamic mechanical analysis to assess viscoelasticity of liver tissue in a rat model of nonalcoholic fatty liver disease. Med Eng Phys. 2017; 44:79-86. DOI: 10.1016/j.medengphy.2017.02.014. View

Alharthi J, Eslam M . Metabolic associated fatty liver disease (MAFLD): a milestone in the history of fatty liver disease. Hepatobiliary Surg Nutr. 2021; 10(5):696-698. PMC: 8527417. DOI: 10.21037/hbsn-21-269. View

Kitae A, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M . The Triglyceride and Glucose Index Is a Predictor of Incident Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Can J Gastroenterol Hepatol. 2019; 2019:5121574. PMC: 6800935. DOI: 10.1155/2019/5121574. View

Christen T, Sheikine Y, Rocha V, Hurwitz S, Goldfine A, Di Carli M . Increased glucose uptake in visceral versus subcutaneous adipose tissue revealed by PET imaging. JACC Cardiovasc Imaging. 2010; 3(8):843-51. PMC: 4042675. DOI: 10.1016/j.jcmg.2010.06.004. View

Softic S, Kahn C . Fatty liver disease: is it nonalcoholic fatty liver disease or obesity-associated fatty liver disease?. Eur J Gastroenterol Hepatol. 2018; 31(1):143. PMC: 6448575. DOI: 10.1097/MEG.0000000000001279. View

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A . The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6:33. PMC: 1636651. DOI: 10.1186/1471-230X-6-33. View

10.

Kodama Y, Ng C, Wu T, Ayers G, Curley S, Abdalla E . Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol. 2007; 188(5):1307-12. DOI: 10.2214/AJR.06.0992. View

11.

Sanyal A, Brunt E, Kleiner D, Kowdley K, Chalasani N, Lavine J . Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011; 54(1):344-53. PMC: 4014460. DOI: 10.1002/hep.24376. View

12.

Jiang W, Liu C, Wu D, Wang Y, Tang H . Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan. Biosci Rep. 2021; 41(12). PMC: 8685641. DOI: 10.1042/BSR20211769. View

13.

Kleiner D, Brunt E, Wilson L, Behling C, Guy C, Contos M . Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019; 2(10):e1912565. PMC: 6784786. DOI: 10.1001/jamanetworkopen.2019.12565. View

14.

Glaudemans A, de Vries E, Galli F, Dierckx R, Slart R, Signore A . The use of (18)F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol. 2013; 2013:623036. PMC: 3763592. DOI: 10.1155/2013/623036. View

15.

Lo G, Besa C, King M, Kang M, Stueck A, Thung S . Feasibility and reproducibility of liver surface nodularity quantification for the assessment of liver cirrhosis using CT and MRI. Eur J Radiol Open. 2017; 4:95-100. PMC: 5524318. DOI: 10.1016/j.ejro.2017.07.001. View

16.

Rozenblum L, Mokrane F, Yeh R, Sinigaglia M, Besson F, Seban R . Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach. Eur J Radiol. 2019; 122:108743. DOI: 10.1016/j.ejrad.2019.108743. View

17.

Pirmoazen A, Khurana A, El Kaffas A, Kamaya A . Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease. Theranostics. 2020; 10(9):4277-4289. PMC: 7086372. DOI: 10.7150/thno.40249. View

18.

Alam S, Fahim S . Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease. World J Hepatol. 2021; 13(10):1203-1207. PMC: 8568582. DOI: 10.4254/wjh.v13.i10.1203. View

19.

Kim Y, Kim J, Jang S, Chung H, Jang K, Paik S . F-18 FDG uptake in focal fatty infiltration of liver mimicking hepatic malignancy on PET/CT images. Clin Nucl Med. 2011; 36(12):1146-8. DOI: 10.1097/RLU.0b013e3182335f60. View

20.

Kang S, Lee H, Yoo J, Cho Y, Kim S, Lee T . KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021; 27(3):363-401. PMC: 8273632. DOI: 10.3350/cmh.2021.0178. View